{"id":519138,"date":"2025-08-08T00:00:00","date_gmt":"2025-08-08T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfmd0015-2025-biopharma-membranous-nephropathy-landscape-forecast-disease-landscape-forecast-g7\/"},"modified":"2026-04-22T23:11:53","modified_gmt":"2026-04-22T23:11:53","slug":"dlsfmd0015-2026-biopharma-membranous-nephropathy-landscape-forecast-disease-landscape-forecast-g7","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfmd0015-2026-biopharma-membranous-nephropathy-landscape-forecast-disease-landscape-forecast-g7\/","title":{"rendered":"Membranous Nephropathy &#8211; Landscape &#038; Forecast &#8211; Disease Landscape &#038; Forecast (G7)"},"content":{"rendered":"<p>Primary membranous nephropathy (<abbr title=\"primary membranous nephropathy\">pMN<\/abbr>), the most common type of <abbr title=\"membranous nephropathy\">MN<\/abbr>, is a rare autoantibody-mediated autoimmune kidney disease. Despite being one of the leading causes of nephrotic syndrome in nondiabetic adults, <abbr title=\"primary membranous nephropathy\">pMN<\/abbr> does not have an approved therapy. Current treatment involves the use of off-label therapies to alleviate clinical symptoms and <abbr title=\"primary membranous nephropathy\">pMN<\/abbr> complications and to delay the onset of end-stage renal disease. However, our understanding of the disease is making major strides. The discovery of PLA2R as a target antigen in almost 80% of <abbr title=\"primary membranous nephropathy\">pMN<\/abbr> patients and the introduction of rituximab in the treatment algorithm exemplify the evolving concepts to manage the disease. Over the 2024-2034 period, we anticipate the <abbr title=\"primary membranous nephropathy\">pMN<\/abbr> therapy market to radically transform through the launch of several therapies. Next-generation CD20- and CD38-targeting antibodies as well as <abbr title=\"Bruton\u2019s tyrosine kinase\">BTK<\/abbr> inhibitors, are some leading candidates looking to capture <abbr title=\"primary membranous nephropathy\">pMN<\/abbr> drug approval.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What percentage of <abbr title=\"primary membranous nephropathy\">pMN<\/abbr> patients receive drug treatment? How do physicians use current off-label therapies to treat the disease?<\/li>\n<li>What are <abbr title=\"key opinion leader\">KOL<\/abbr>s\u2019 views of late-phase candidates (Roche\u2019s obinutuzumab, Biogen\u2019s felzartamab, BeOne medicines\u2019 zanubrutinib)?<\/li>\n<li>How will emerging therapies influence the treatment landscape and affect prescribing decisions?<\/li>\n<li>What are the <abbr title=\"primary membranous nephropathy\">pMN<\/abbr> therapy market\u2019s key drivers and constraints, and how will the market evolve over the forecast period?<\/li>\n<li>What are the unmet needs in the treatment of <abbr title=\"primary membranous nephropathy\">pMN<\/abbr>, and how likely are they to be fulfilled during the forecast period?<\/li>\n<\/ul>\n<div>\n<p style=\"\"><strong>Geography:\u00a0<\/strong>United States, <abbr title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr>, Japan<\/p>\n<\/div>\n<div>\n<p style=\"\"><strong>Primary research:\u00a0<\/strong>Country-specific interviews with thought-leading nephrologists. Survey data collected for this and other Clarivate research.<\/p>\n<\/div>\n<div>\n<p style=\"\"><strong>Epidemiology:\u00a0<\/strong>Diagnosed incidence of <abbr title=\"primary membranous nephropathy\">pMN<\/abbr> by country, clinically and market relevant drug-treatable populations<\/p>\n<\/div>\n<div>\n<p style=\"\"><strong>Forecast:\u00a0<\/strong>10-year, annualized, drug-level sales and patient share of key membranous nephropathy therapies through 2034, segmented by brands \/ generics and epidemiological subpopulations<\/p>\n<\/div>\n<div>\n<p style=\"\"><strong>Drug treatments:<\/strong> Coverage of key current and late-phase emerging therapies<\/p>\n<\/div>\n<p><strong>Product description<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:<\/p>\n<ul class=\"round-bullets\">\n<li>Optimize your long-term disease and development strategy.<\/li>\n<li>Quantify market potential for your pipeline assets and those of your competitors.<\/li>\n<li>Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-519138","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/519138","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/519138\/revisions"}],"predecessor-version":[{"id":575746,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/519138\/revisions\/575746"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=519138"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}